Search
Now showing items 1-2 of 2
Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix1) Pilot Project in Uganda
(2016)
The objective of this study was to determine the prevalence and some predictors for vaccine
and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated
young women in Uganda. This was a ...
Feasibility of delivering HPV vaccine to girls aged 10 to 15 years in Uganda
(African health sciences, 2015)
Background: Cervical cancer is a leading cause of mortality among women in Uganda. The availability of the human papillomavirus
(HPV) vaccine presents an opportunity to prevent cervical cancer. The Government of Uganda ...